Business
Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A look at how two biotech professionals made the transition from research to inspiring students as biotech teachers with the help of EnCorps STEM Teachers Program.
Christopher Anzalone, Arrowhead’s chief executive officer, took time to speak with BioSpace about the company’s large pipeline and why they’re so excited about 2020.
After four years with the gene therapy company, Chief Medical Officer Kathleen Reape will resign her position.
The changes are designed to extend the company’s cash runway to the end of 2021.
With the acquisition of San Diego-based PvP Biologics and a recent deal with COUR Pharmaceuticals, Takeda Pharmaceutical is looking to become a world leader in the treatment of celiac disease and other gastrointestinal disorders.
A group of researchers at Purdue University identified an epigenetic process that controls the behavior of stem cell enhancers.
A federal judge has ruled that a decade’s worth of unpublished clinical trial data from drug companies, universities and other agencies involved, must now be made public.
Cellbox Solutions announces the expansion of its Board of Directors and the appointment of a new CEO - Wolfgang Kintzel will start as Chief Executive Officer effective March 1, 2020.
In its announcement, Bicycle did not identify the cancer targets it will focus on in its collaboration with Genentech.
Mallinckrodt Files Chapter 11 for its Generics Business as it Reaches $1.6 Billion Opioid Settlement
In addition to the settlement and bankruptcy, Mallinckrodt entered into a debt refinancing agreement, including an $800 million loan that will be used to repay some outstanding debt and acquire some outstanding stocks.